Prostacyclin Usage for Spinal Cord Protection During Experimental Thoracic Aortic Cross-Clamping

Salih Katircioğlu; Perran Gökce; Eser Özgencil; Zuilfikar Saritas; Erol Sener; Bayram Yilmazkaya; Bahattin Koc; Oğuz Tasdemir; Kemal Bayazit

doi:10.1177/153857449603000203

$The risk of paraplegia associated with thoracic aortic cross-clamping is high even when various methods of spinal cord protection are used. In this study prostacyclin 12 (PGI 2 ) was selected as an agent to reduce the spinal cord injury because of its vasodilator, antiaggregant, and cytoprotective properties. Twelve dogs underwent sixty-minute aortic occlusion. Six dogs received PGI 2 whereas the other 6 did not (controls). PG1 2 administration was started at a rate of 5 ng/kg/minute five minutes before aortic occlusion. This dosage was increased to 25 ng/kg/minute during aortic occlusion. PGI 2 at a dosage of 5 ng/kg/minute was maintained for a period of five minutes after the aortic occlusion was released. Three dogs in the control group were paraplegic. There were no paraplegic dogs in the PGI 2 group. Distal aortic perfusion pressure was 31 \xB1 mmHg in the PGI 2 group and 22 \xB13 in the control group (P <0.008). As a result of this study the authors conclude that PGI 2 is a valuable agent for decreasing the risk of spinal cord injury during thoracic aortic cross-clamping lasting sixty minutes.$

Prostacyclin Usage for Spinal Cord Protection During Experimental Thoracic Aortic Cross-Clamping

Katircioğlu, Salih; Gökce, Perran; Özgencil, Eser; Saritas, Zuilfikar; Sener, Erol; Yilmazkaya, Bayram; Koc, Bahattin; Tasdemir, Oğuz; Bayazit, Kemal

Follow Vascular and Endovascular Surgery , Volume 30 (2) SAGE – Jan 1, 1996